Ontuxizumab
Ontuxizumab is a monoclonal antibody designed for the treatment of cancer. This drug was developed by Morphotek.
History[edit]
Ontuxizumab was developed by Morphotek, a subsidiary of Eisai Co.. The drug is a monoclonal antibody that targets endosialin, a protein that is overexpressed in many types of cancer.
Mechanism of Action[edit]
Ontuxizumab works by targeting endosialin, a protein that is overexpressed in many types of cancer. By binding to this protein, ontuxizumab can inhibit the growth and spread of cancer cells.
Clinical Trials[edit]
Ontuxizumab has been tested in several clinical trials for its effectiveness in treating various types of cancer. These trials have shown promising results, but further research is needed to confirm these findings.
Side Effects[edit]
Like all drugs, ontuxizumab can cause side effects. The most common side effects reported in clinical trials include fatigue, nausea, and decreased appetite. More serious side effects can also occur, but these are less common.
See Also[edit]
References[edit]
<references />
 | This medical article is a stub. You can help WikiMD by expanding the page. |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
